AI Article Synopsis
- The study compares the projected costs and time burdens for US patients with myelofibrosis and anemia treated with momelotinib versus danazol, based on data from the MOMENTUM trial and earlier research.
- It indicates that momelotinib leads to significant reductions in transfusion frequency, resulting in lower annual medical costs ($53,143 vs. $46,455) and outpatient transfusion costs ($42,021 vs. $8,370) for transfusion-dependent and independent patients.
- Additionally, patients treated with momelotinib are expected to save an average of 173 hours for transfusion-dependent and 35 hours for transfusion-independent patients, highlighting benefits in both
Article Abstract
To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol. Cost and time burden were calculated based on the transfusion status of patients in the MOMENTUM trial and estimates extracted from previous studies. Reductions in transfusion associated with momelotinib are projected to result in cost and time savings compared with danazol in transfusion-dependent and transfusion-independent/requiring patients with myelofibrosis, respectively: annual medical costs ($53,143 and $46,455 per person), outpatient transfusion costs ($42,021 and $8,370 per person) and annual time savings (173 and 35 h per person). Fewer transfusions with momelotinib are projected to result in cost and time savings in patients with myelofibrosis and anemia compared with danazol.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508939 | PMC |
| http://dx.doi.org/10.1080/14796694.2024.2368450 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis.
Leukemia
December 2024
Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Although multiple genetic events are thought to play a role in promoting progression of the myeloproliferative neoplasms (MPN), the individual events that are associated with the development of more aggressive disease phenotypes remain poorly defined. Here, we report that novel genomic deletions at chromosome 12q14.3, as detected by a high-resolution array comparative genomic hybridization plus single nucleotide polymorphisms platform, occur in 11% of MPN patients with myelofibrosis (MF) and MPN-accelerated/blast phase (AP/BP) but was not detected in patients with polycythemia vera or essential thrombocythemia.
View Article and Find Full Text PDFMolecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients.
Hamostaseologie
December 2024
Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
Background: The risk of thrombosis and bleeding in myelofibrosis (MF) has been historically underappreciated. We sought to investigate potential molecular and clinical risk factors for venous (VTE) and arterial (ATE) thrombotic events as well as bleeding episodes.
Methods: Data from 246 consecutive MF patients were analyzed.
Whole exome sequencing analysis of a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene.
Ann Hematol
December 2024
Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
ETV6::LYN fusion gene is recognized as one of the genetic alterations responsible for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) according to the 2022 WHO classification. However, the clinical features and pathogenesis of MLN-TK with ETV6::LYN are not well defined because of the rarity of the disease. Here, we report an MLN-TK patient with ETV6::LYN that manifested as myeloproliferative neoplasms (MPN) with eosinophilia, myelofibrosis, and T-lymphoblastic lymphoma (T-LBL), which eventually led to acute myeloid leukemia.
View Article and Find Full Text PDFExtramedullary Hematopoiesis in Serous Cavity Fluids: A Closer Look at This Rare Phenomenon With Diagnostic Pitfalls and Prognostic Significance.
Diagn Cytopathol
December 2024
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Extramedullary hematopoiesis (EMH) is usually seen in the reticuloendothelial system such as the spleen and liver; however, there have been rare case reports when EMH is seen in serous fluids (SFs). The aim of this study included analyzing the cytomorphological features of EMH in SFs in correlation with various clinicopathologic parameters and recognizing potential diagnostic pitfalls as well as their prognostic significance.
Methods: Clinicopathologic parameters and radiologic and pathologic information from the patients with a cytologic diagnosis of EMH were evaluated with cytology slides.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!